# *n*-Bu<sub>4</sub>NI-catalyzed selective dual amination of sp<sup>3</sup> C–H bonds: oxidative domino synthesis of imidazo[1,5-*c*]quinazolines on a gram-scale

Dan Zhao, Teng Wang, Qi Shen and Jian-Xin Li\*

State Key Lab of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210093, P. R. China. Fax: +86-25-83686419; E-mail: <u>lijxnju@nju.edu.cn</u>

#### **Electronic Supplementary Information**

#### Content

General information	<b>S2</b>
Optimization of the reaction condition	S2–S4
General procedure for the synthesis of substrates and products	<b>S4–S6</b>
Control experiments on the reaction mechanism	<b>S7–S8</b>
Substrate characterizations	<b>S9–S13</b>
Product and intermediate 6 characterizations	S14–S23
References	S23
Spectral copies of <sup>1</sup> H- and <sup>13</sup> C-NMR of products and intermediate 6	S24–S59

#### **General information**

All commercial reagents and solvents were used without additional purification unless otherwise specified. Melting points were measured with an X-4 melting point apparatus (Bei Jing Taike Co., Ltd.) and were uncorrected. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR were determined in CDCl<sub>3</sub> on a Bruker DPX 300 MHz or a Bruker AVANCE III 400 MHz spectrometer at room temperature, respectively, and tetramethylsilane (TMS) served as an internal standard. Spin multiplicities are given as s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet) as well as brs (broad). Coupling constants (*J*) are given in hertz (Hz). ESI-MS was carried out on a LCMS-2020 (Shimadzu, Japan). HRMS were recorded on a LTQ-Orbitrap XL (Thermofisher, U.S.A.). All experiments were monitored by thin layer chromatography (TLC). TLC was performed on pre-coated silica gel plates (Qingdao Haiyang Chemical Co., Ltd).

#### **Optimization of the reaction condition**

 Table S1 Screening of Reaction Conditions<sup>a</sup>

		$ \begin{array}{c}                                     $	I + H <sub>2</sub> N Ph 20 mol% XI / Oxidant Ph Additive, Solvent Temperature, Time		- N Ph N Ph 3aa		
Ent	XI	Oxidant	Additive (equiv)	Solvent	Temp.	Time	Yield <sup>b</sup>
ry		(equiv)			(°C)	(h)	(%)
1	<i>n</i> -Bu <sub>4</sub> NI	5.5 M TBHP		DMSO	90	10	36
		in decane (4)					
2		5.5 M TBHP		DMSO	90	10	nd
		in decane (4)					
3	NIS	5.5 M TBHP		DMSO	90	10	26
		in decane (4)					
4	$I_2$	5.5 M TBHP		DMSO	90	10	23
		in decane (4)					
5	PhI	5.5 M TBHP		DMSO	90	10	nd
		in decane (4)					
6	KI	5.5 M TBHP		DMSO	90	10	33
		in decane (4)					
7	<i>n</i> -Bu <sub>4</sub> NI	1atm air		DMSO	90	10	nd
8	<i>n</i> -Bu <sub>4</sub> NI	30% Aq.		DMSO	90	10	trace
		$H_2O_2(4)$					
9	<i>n</i> -Bu <sub>4</sub> NI	$(tBuO)_2(4)$		DMSO	90	10	nd
10	<i>n</i> -Bu <sub>4</sub> NI	$K_2S_2O_8(4)$		DMSO	90	10	messy
11	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.		DMSO	90	10	37
		TBHP (4)					
12	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$K_{2}CO_{3}(2)$	DMSO	90	10	messy
		TBHP (4)					
13	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(2)$	DMSO	90	10	80
		TBHP (4)					

14	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	CF <sub>3</sub> COOH (2)	DMSO	90	10	messy
		TBHP (4)		51460		10	
15	n-Bu <sub>4</sub> NI	70% Aq.	PhCOOH (2)	DMSO	90	10	72
16	D M	TBHP (4)		DMGO	00	10	70
16	n-Bu <sub>4</sub> NI	70% Aq.	$PhCH_2COOH(2)$	DMSO	90	10	/8
17	D., MI	1 BHP (4)		DMCO	00	10	47
1 /	<i>n</i> -Bu <sub>4</sub> INI	70% Aq.	$0 - C_6 H_4(COOH)_2(2)$	DMSO	90	10	47
10	n Du MI	ТВПР (4) 70% Ад		DMSO	00	10	65
18	<i>n</i> -Du <sub>4</sub> INI	70% Аq. Трир (4)	$CH_3CH_2COOH(2)$	DMSO	90	10	03
10	n-Bu NI	70% Ag	СН.(СН.).СООН (2)	DMSO	90	10	78
19		7078 Aq. TBHP (4)	$CI1_3(CI1_2)_3COOII(2)$	DWBO	90	10	78
20	n-Bu.NI	70% Ag	$N_{2}H_{2}PO(2H_{2}O(2))$	DMSO	90	10	67
20		7070 Aq. TBHP (4)	112104 21120(2)	DWBO	<i>)</i> 0	10	07
21	n-Bu₄NI	70% Aa	$CH_2COOH(2)$	DMF	90	10	40
21	n Du <sub>4</sub> r (1	TBHP (4)	011,00011 (2)	Dim	20	10	10
22	<i>n</i> -Bu₄NI	70% Ag	CH <sub>2</sub> COOH (2)	DMA	90	10	46
	n Dugi (I	TBHP (4)		Dimi	20	10	10
23	<i>n</i> -Bu₄NI	70% Aq.	CH <sub>3</sub> COOH (2)	toluene	90	10	22
		TBHP (4)					
24	<i>n</i> -Bu₄NI	70% Aq.	CH <sub>3</sub> COOH (2)	CH <sub>3</sub> CN	90	10	26
		TBHP (4)		-			
25	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	CH <sub>3</sub> COOH (2)	dioxane	90	10	26
		TBHP (4)					
26	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	CH <sub>3</sub> COOH (2)	DCE	90	10	23
		<b>TBHP</b> (4)					
27	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(2)$	NMP	90	10	40
		<b>TBHP</b> (4)					
28	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	CH <sub>3</sub> COOH (2)	$H_2O$	90	10	30
		<b>TBHP</b> (4)					
29	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(1)$	DMSO	90	10	61
		TBHP (4)					
30	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	<b>CH</b> <sub>3</sub> <b>COOH</b> (3)	DMSO	90	10	88
		<b>TBHP (4)</b>					
31	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(4)$	DMSO	90	10	86
		TBHP (4)					
32	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(3)$	DMSO	100	10	81
		TBHP (4)					
33	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(3)$	DMSO	110	10	79
		TBHP (4)					
34	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(3)$	DMSO	75	10	58
• -	<b>P</b>	TBHP (4)		D: (7 -	~~		0.5
35	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(3)$	DMSO	90	12	81
		<b>TBHP</b> (4)					

36	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	CH <sub>3</sub> COOH (3)	DMSO	90	15	81
		TBHP (4)					
37	<i>n</i> -Bu <sub>4</sub> NI	70% Aq.	$CH_3COOH(3)$	DMSO	90	10	65
		TBHP (2)					

<sup>*a*</sup> Reaction conditions: **1a** (0.3 mmol), **2a** (0.6 mmol), XI (20 mol%), oxidant (indicated amount), additive (indicated amount), in a tested solvent (2 mL) at a selected temperature. nd = not detected. <sup>*b*</sup> Isolated yield.

#### General procedure for the synthesis of substrates and products General procedure for the synthesis of 4-methylquinazolines (1a–o, 1s and 1t):



To a solution of 2-aminoacetophenone derivatives (20 mmol) and triethylamine (3.3 mL, 1.2 equiv) in dichloromethane (DCM) (60 mL) cooled in an ice-water bath, chloride (1.5 equiv) was added dropwise. The progress of the reaction was monitored by TLC. Upon completion, the solution was washed with diluted hydrochloric acid, saturated NaHCO<sub>3</sub>, brine, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The organic phase was concentrated in vacuo to give amide as an intermediate without further purification. The amide, 25% ammonia water (20 mL) and isopropanol (20 mL) were added to a 250 mL sealed tube. The tube was located in a preheated 90 °C oil bath and stirred for 10 h. The reaction mixture was cooled to room temperature, washed with diluted hydrochloric acid, saturated NaHCO<sub>3</sub>, brine, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, then concentrated in vacuo. The residue was then purified by chromatography on silica gel with an eluent of petroleum ether and ethyl acetate. Products were characterized by Mp, <sup>1</sup>H-, <sup>13</sup>C-NMR and MS (ESI).

#### Procedure for the synthesis of 4-methylquinazolines (1p-r):



To a solution of 2-aminoacetophenone derivatives (20 mmol) and triethylamine (3.3 mL, 1.2 equiv) in dichloromethane (DCM) (60 mL) cooled in an ice-water bath, trichloroacetyl chloride (1.2 equiv) was added dropwise. The progress of the reaction was monitored by TLC. Upon completion, the solution

was washed with diluted hydrochloric acid, saturated NaHCO<sub>3</sub>, brine, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The organic phase was concentrated in vacuo to give amide as an intermediate without further purification. Ammonium carbamate (5 equiv) was added to a solution of amide in methanol (40 mL). The mixture was stirred at about 40 °C for 8 h. The excess ammonium carbamate was filtered. The organic phase was concentrated in vacuo and the gray residue was recrystallized from ethyl acetate/hexanes 1/3 (v/v) to give 4-methylquinazolin-2(1H)-one (76% yield for two steps). POCl<sub>3</sub> (5 mL) was added drop wise to 4-methylquinazolin-2(1H)-one (10 mmol) at 0 °C. The mixture was refluxed for 3 h. Excess POCl<sub>3</sub> was distilled off and the residue was cooled to room temperature and then added drop wise into crushed ice. The aqueous layer was extracted with ethyl acetate, washed with saturated NaHCO<sub>3</sub>, brine, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, then concentrated in vacuo. The residue was then purified by chromatography on silica gel with an eluent of petroleum ether and ethyl acetate to give **1p** (48% yield). To a solution of **1p** (2 mmol) in methanol (5 mL), secondary amine (1.2 equiv) and triethylamine (4 equiv) were added. The mixture was refluxed for 3 h. The solvent was distilled off and the residue was then purified by chromatography on silica gel with an eluent of petroleum ether and ethyl acetate to give 1q (87% yield) and 1r (86% yield). Products were characterized by Mp, <sup>1</sup>H-, <sup>13</sup>C-NMR and MS (ESI).

#### Procedure for the synthesis of 4-methyl-2-phenylpyrimidine (1u):



To a round-bottom flask was added 2-chloro-4-methylpyrimidine (2 mmol), arylboronic acid (2 equiv),  $PdCl_2(PPh_3)_2$  (4 mol%) and  $Na_2CO_3$  (2 M, 5 mL) in dioxane (5 mL). The reaction mixture was heated to 90 °C until the 2-chloro-4-methylpyrimidine was consumed completely. The heterogeneous aqueous was concentrated in vacuo and the residue was diluted with EtOAc, washed by brine. The organic layer was dried over anhydrous  $Na_2SO_4$ , concentrated and then purified by chromatography on silica gel with an eluent of petroleum ether and ethyl acetate to give **1u** (100% yield).

#### General procedure for the synthesis of substituted imidazo[1,5-*c*]quinazolines (3):

A mixture of 4-methylquinazoline **1** (0.3 mmol), benzylamine **2** or amino acid **4** (0.6 mmol), *n*-Bu<sub>4</sub>NI (0.06 mmol), TBHP (1.2 mmol, 70% in water) and acetic acid (0.9 mmol) in 2 mL DMSO was stirred in a Schlenk tube at 90 °C. After stirring for 10 h, the reaction mixture was cooled to the room temperature, and extracted by ethyl acetate ( $3 \times 5$  mL). The organic phase was then washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was then purified by chromatography on silica gel with an eluent of petroleum ether and ethyl acetate. Products were characterized by Mp, <sup>1</sup>H-, <sup>13</sup>C-NMR and HRMS (ESI).

#### The failure examples:





#### Control experiments on the reaction mechanism

Scheme S1 Control reactions A-F.





(a)

tBuOOH

tBuO + HO

Scheme S2 Plausible reaction mechanism.

Substrate characterizations



4-*Methyl-2-phenylquinazoline* (*1a*)<sup>*I*</sup>. white solid, 76% yield for two steps, mp. 84 – 85 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.63 (dd, *J* = 7.9, 1.8 Hz, 2H), 8.09 (d, *J* = 8.3 Hz, 2H), 7.87 (ddd, *J* = 8.5, 6.9, 1.3 Hz, 1H), 7.64 – 7.45 (m, 4H), 3.02 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.1, 160.0, 150.2 138.2, 133.4, 130.3, 129.1, 128.48, 128.52, 126.7, 124.8, 122.8, 21.9; MS (ESI): 221.00 [M+H]<sup>+</sup>.



2-(4-(*Tert-butyl*)*phenyl*)-4-*methylquinazoline* (**1b**). colorless oil, 91% yield for two steps. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.65 – 8.43 (m, 2H), 8.08 (d, *J* = 8.4 Hz, 2H), 7.85 (ddd, *J* = 8.3, 6.9, 1.4 Hz, 1H), 7.62 – 7.50 (m, 3H), 3.01 (s, 3H), 1.39 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  167.9, 160.1, 153.5, 150.3, 135.6, 133.2, 129.0, 128.3, 126.5, 125.4, 124.8, 122.8, 34.8, 31.3, 21.9; MS (ESI): 277.15 [M+H]<sup>+</sup>; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>21</sub>N<sub>2</sub> [M+H]<sup>+</sup> 277.1699, found 277.1696.



2-(4-Methoxyphenyl)-4-methylquinazoline  $(1c)^1$ . white solid, 80% yield for two steps, mp. 112 – 113 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.69 – 8.46 (m, 2H), 8.14 – 7.98 (m, 2H), 7.83 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.54 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.11 – 6.97 (m, 2H), 3.90 (s, 3H), 2.99 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  168.0, 161.6, 159.9, 150.3, 133.4, 130.9, 130.1, 128.9, 126.3, 124.9, 122.6, 113.8, 55.3, 21.9; MS (ESI): 251.10 [M+H]<sup>+</sup>.



4-*Methyl*-2-(4-(*trifluoromethyl*)*phenyl*)*quinazoline* (1*d*)<sup>2</sup>. white solid, 95% yield for two steps, mp. 86 – 87 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.75 (d, *J* = 8.1 Hz, 2H), 8.20 – 8.03 (m, 2H), 7.90 (ddd, *J* = 8.5, 6.9, 1.3 Hz, 1H), 7.77 (d, *J* = 8.3 Hz, 2H), 7.63 (ddd, *J* = 8.1, 7.0, 1.1 Hz, 1H), 3.03 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.5, 158.6, 150.2, 141.6, 133.7, 131.8 (q, *J*<sub>C-F</sub> = 32.2 Hz), 129.3, 128.8, 127.4, 125.4 (q, *J*<sub>C-F</sub> = 3.8 Hz), 125.0, 124.3 (d, *J*<sub>C-F</sub> = 272.2 Hz), 123.2, 21.9; MS (ESI): 289.05 [M+H]<sup>+</sup>.



4-*Methyl-2-(4-nitrophenyl)quinazoline (1e)*<sup>3</sup>. yellow solid, 38% yield for two steps, mp. 171 – 172 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.79 (d, *J* = 8.7 Hz, 2H), 8.33 (d, *J* = 8.7 Hz, 2H), 8.10 (t, *J* = 8.1 Hz, 2H), 7.91 (t, *J* = 7.6 Hz, 1H), 7.65 (t, *J* = 7.6 Hz, 1H), 3.03 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.6, 158.0, 150.9, 150.1, 150.0, 135.6, 133.6, 129.1, 127.2, 124.8, 123.1, 123.0, 21.8; MS (ESI): 266.00 [M+H]<sup>+</sup>.



*2-(3-Chlorophenyl)-4-methylquinazoline (*1f)<sup>*4*</sup>. yellow solid, 64% yield for two steps, mp. 106 – 107 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.65 – 8.61 (m, 1H), 8.55 – 8.47 (m, 1H), 8.13 – 8.03 (m, 2H), 7.87 (ddd, *J* = 8.3, 6.9, 1.3 Hz, 1H), 7.60 (ddd, *J* = 8.3, 6.9, 1.3 Hz, 1H), 7.47 – 7.43 (m, 2H), 3.01 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  168.4, 158.7, 150.2, 140.1, 134.6, 133.6, 130.2, 129.7, 129.2, 128.5, 127.1, 126.5, 124.9, 123.1, 21.9; MS (ESI): 255.05 [M+H]<sup>+</sup>.



2-(2-Fluorophenyl)-4-methylquinazoline (**1g**). white solid, 57% yield for two steps, mp. 63 – 64 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.18 – 8.06 (m, 3H), 7.90 (t, *J* = 7.8 Hz, 1H), 7.64 (t, *J* = 7.6 Hz, 1H), 7.52 – 7.39 (m, 1H), 7.36 – 7.14 (m, 2H), 3.03 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  168.3, 162.7, 159.4, 158.9 (d, *J*<sub>C-F</sub> = 3.9 Hz), 150.0, 133.6, 132.0, 131.2 (d, *J*<sub>C-F</sub> = 8.5 Hz), 129.1, 127.4, 124.8, 124.1 (d, *J*<sub>C-F</sub> = 3.4 Hz), 122.5, 116.7 (d, *J*<sub>C-F</sub> = 22.3 Hz), 21.8; MS (ESI): 239.00 [M+H]<sup>+</sup>; HRMS (ESI) m/z calcd for C<sub>15</sub>H<sub>12</sub>FN<sub>2</sub> [M+H]<sup>+</sup> 239.0979, found 239.0983.



2-(*Furan-2-yl*)-4-methylquinazoline (1h)<sup>5</sup>. white solid, 93% yield for two steps, mp. 82 – 83 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 – 8.00 (m, 2H), 7.84 (ddd, J = 8.5, 7.0, 1.3 Hz, 1H), 7.68 (dd, J = 1.7, 0.8 Hz, 1H), 7.55 (ddd, J = 8.1, 7.0, 1.0 Hz, 1H), 7.45 (dd, J = 3.4, 0.8 Hz, 1H), 6.60 (dd, J = 3.4, 1.8 Hz, 1H), 2.97 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  168.6, 153.2, 152.6, 149.8, 145.0, 133.7, 128.8, 126.8, 124.9, 122.7, 113.7, 112.1, 21.8; MS (ESI): 211.05 [M+H]<sup>+</sup>.



*4-Methyl-2-(thiophen-2-yl)quinazoline (1i)*<sup>6</sup>. white solid, 89% yield for two steps, mp. 86 – 87 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.15 (dd, *J* = 3.7, 1.2 Hz, 1H), 8.07 – 7.94 (m, 2H), 7.82 (ddd, *J* = 8.4, 6.9, 1.4 Hz, 1H), 7.57 – 7.44 (m, 2H), 7.18 (dd, *J* = 5.0, 3.7 Hz, 1H), 2.96 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  168.3, 156.9, 150.1, 144.1, 133.6, 129.6, 128.9, 128.7, 128.2, 126.5, 125.0, 122.7, 21.8; MS (ESI): 227.05 [M+H]<sup>+</sup>.



*4-Methyl-2-(pyridin-3-yl)quinazoline (1j)*<sup>4</sup>. yellow solid, 71% yield for two steps, mp. 107 – 109 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.81 (s, 1H), 8.88 (d, *J* = 7.9 Hz, 1H), 8.72 (d, *J* = 3.6 Hz, 1H), 8.10 (t, *J* = 8.7 Hz, 2H), 7.89 (t, *J* = 7.6 Hz, 1H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.45 (dd, *J* = 7.8, 4.9 Hz, 1H), 3.03 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  168.1, 157.9, 150.5, 149.9, 149.8, 135.4, 133.4, 128.8, 127.0, 124.7, 122.8, 122.7, 21.7; MS (ESI): 222.00 [M+H]<sup>+</sup>.



1k

2,4-Dimethylquinazoline (1k)<sup>7</sup>. yellow oil, 45% yield for two steps. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.06 (d, *J* = 8.3 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.87 – 7.80 (m, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 2.93 (s, 3H), 2.85 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 168.0, 163.4, 149.8, 133.5, 128.1, 126.5, 124.8, 122.1, 26.3, 21.6; MS (ESI): 159.00 [M+H]<sup>+</sup>.



11

*4-Methyl-2-propylquinazoline* (11)<sup>7</sup>. colorless oil, 73% yield for two steps. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (d, J = 8.3 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.83 (t, J = 7.7 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 3.08 – 3.01 (m, 2H), 2.93 (s, 3H), 2.01 – 1.86 (m, 2H), 1.05 (t, J = 7.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.1, 166.8, 149.9, 133.5, 128.5, 126.6, 124.9, 122.5, 42.0 , 22.4, 21.7, 14.1; MS (ESI): 187.10 [M+H]<sup>+</sup>.

2-(*Tert-butyl*)-4-methylquinazoline (1m)<sup>8</sup>. white solid, 93% yield for two steps, mp. 49 – 50 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.07 – 8.00 (m, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.80 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 7.53 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 2.92 (s, 3H), 1.50 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  172.6, 167.2, 149.7, 132.7, 128.8, 126.2, 124.6, 122.1, 39.3, 29.5, 21.8; MS (ESI): 201.10 [M+H]<sup>+</sup>.



2-*Cyclopropyl-4-methylquinazoline* (*1n*). yellow solid, 92% yield for two steps, mp. 55 – 57 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.90 (d, *J* = 8.3 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 1H), 7.71 (ddd, *J* = 8.3, 6.9, 1.3 Hz, 1H), 7.47 – 7.35 (m, 1H), 2.79 (s, 3H), 2.30 (tt, *J* = 8.2, 4.8 Hz, 1H), 1.31 – 1.11 (m, 2H), 1.13 – 0.94 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  167.8, 167.3, 149.9, 133.2, 128.0, 125.8, 124.8, 122.5, 21.7, 18.4, 10.3; MS (ESI): 185.10 [M+H]<sup>+</sup>; HRMS (ESI) m/z calcd for C<sub>12</sub>H<sub>13</sub>N<sub>2</sub> [M+H]<sup>+</sup> 185.1073 , found 185.1073.



2-*Cyclohexyl-4-methylquinazoline* (10)<sup>3</sup>. yellow solid, 66% yield for two steps, mp. 46 – 48 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.08 – 8.00 (m, 1H), 7.96 (d, *J* = 8.4 Hz, 1H), 7.81 (ddd, *J* = 8.4, 6.9, 1.4 Hz, 1H), 7.54 (ddd, *J* = 8.2, 6.9, 1.1 Hz, 1H), 3.04 – 2.95 (m, 1H), 2.92 (s, 3H), 2.08 – 2.04 (m, 2H), 1.95 – 1.67 (m, 5H), 1.57 – 1.31 (m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.0, 167.8, 150.0, 133.1, 128.6, 126.3, 124.8, 122.6, 47.9, 31.9, 26.4, 26.0, 21.7; MS (ESI): 227.15 [M+H]<sup>+</sup>.



2-*Chloro-4-methylquinazoline* (*1p*)<sup>9</sup>. yellow solid, 48% yield, mp. 110 – 112 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.09 (d, *J* = 8.4 Hz, 1H), 8.01 – 7.86 (m, 2H), 7.65 (ddd, *J* = 8.2, 6.7, 1.4 Hz, 1H), 2.96 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.1, 156.8, 151.4, 134.9, 128.2, 127.9, 125.3, 122.8, 21.7; MS (ESI): 179.10 [M+H]<sup>+</sup>.



*4-Methyl-2-(piperidin-1-yl)quinazoline* (1q)<sup>10</sup>. yellow solid, 87% yield, mp. 74 – 75 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.79 (dd, J = 8.2, 0.7 Hz, 1H), 7.59 (ddd, J = 8.1, 6.7, 1.4 Hz, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.14 (ddd, J = 8.1, 6.7, 1.4 Hz, 1H), 4.14 – 3.51 (m, 4H), 2.75 (s, 3H), 1.75 – 1.57 (dt, J = 9.3, 3.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.6, 158.6, 152.2, 133.3, 126.1, 125.2, 121.6, 118.7, 44.9, 26.0, 25.0, 21.9; MS (ESI): 228.15 [M+H]<sup>+</sup>.



4-(4-Methylquinazolin-2-yl)morpholine (1r)<sup>10</sup>. yellow solid, 86% yield, mp. 48 – 50 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.84 (dd, J = 8.2, 0.8 Hz, 1H), 7.63 (ddd, J = 8.2, 6.7, 1.4 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.21 (ddd, J = 8.1, 6.7, 1.3 Hz, 1H), 4.06 – 3.89 (m, 4H), 3.85 – 3.70 (m, 4H), 2.78 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.0, 158.5, 151.9, 133.6, 126.3, 125.3, 122.4, 119.2, 67.1, 44.5, 21.9; MS (ESI): 230.15 [M+H]<sup>+</sup>.



8-*Methyl-6-phenyl-[1,3]dioxolo[4,5-g]quinazoline (1s)*<sup>1</sup>. white solid, 21% yield for two steps, mp. 185 – 187 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.63 – 8.44 (m, 2H), 7.56 – 7.39 (m, 3H), 7.29 (s, 1H), 7.23 (s, 1H), 6.09 (s, 2H), 2.85 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 165.2, 159.2, 153.4, 149.8, 147.9, 138.4, 130.0, 128.5 128.2, 119.6, 105.4, 102.1, 100.3, 22.2; MS (ESI): 265.10 [M+H]<sup>+</sup>.



*4-Methyl-2-phenylpyrido*[2,3-*d*]*pyrimidine* (1*t*). red solid, 70% yield for two steps, mp. 97 – 99 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  9.21 (dd, *J* = 4.3, 1.9 Hz, 1H), 8.81 – 8.65 (m, 2H), 8.44 (dd, *J* = 8.2, 2.0 Hz, 1H), 7.64 – 7.44 (m, 4H), 3.02 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.2, 163.5, 158.6, 157.6, 137.4, 134.4, 131.2, 129.2, 128.5, 122.3, 117.6, 21.6; HRMS (ESI) m/z calcd for C<sub>14</sub>H<sub>12</sub>N<sub>3</sub> [M+H]<sup>+</sup> 222.1026, found 222.1021.



4-*Methyl-2-phenylpyrimidine* (1*u*)<sup>11</sup>. yellow oil, 100% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.64 (d, J = 5.1 Hz, 1H), 8.50 – 8.32 (m, 2H), 7.57 – 7.39 (m, 3H), 7.04 (d, J = 5.0 Hz, 1H), 2.59 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  167.3, 164.4, 156.8, 137.8, 130.5, 128.5, 128.2, 118.6, 24.4; MS (ESI): 171.10 [M+H]<sup>+</sup>.

#### Product and intermediate 6 characterizations



3,5-Diphenylimidazo[1,5-c]quinazoline (**3aa**). yellow solid, 88% yield, mp. 142 – 145 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 – 8.05 (m, 1H), 8.04 (s, 1H), 7.95 – 7.88 (m, 1H), 7.60 – 7.53 (m, 2H), 7.34 (d, *J* = 7.4 Hz, 2H), 7.23 – 6.97 (m, 8H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  146.2, 142.7, 138.1, 133.8, 131.4, 130.3, 129.9, 129.2, 128.6, 128.5, 128.2, 128.0, 127.7, 127.4, 121.7, 120.6, 119.3; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>16</sub>N<sub>3</sub> [M+H]<sup>+</sup> 322.1339, found 322.1338.



5-Phenyl-3-(o-tolyl)imidazo[1,5-c]quinazoline (**3ab**). yellow solid, 83% yield, mp. 146 – 148 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.12 – 8.06 (m, 1H), 8.05 (s, 1H), 7.94 – 7.86 (m, 1H), 7.63 – 7.49 (m, 2H), 7.35 – 7.27 (m, 2H), 7.19 – 7.10 (m, 1H), 7.08 – 6.93 (m, 4H), 6.92 – 6.84 (m, 2H), 2.06 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 146.4, 141.6, 138.0, 137.0, 133.1, 131.6, 130.8, 129.7, 129.6, 129.5, 128.8, 128.5, 128.4, 128.2, 127.3, 125.1, 121.7, 120.3, 119.4, 20.1; HRMS (ESI) m/z calcd for  $C_{23}H_{18}N_3$  [M+H]<sup>+</sup> 336.1495, found 336.1495.



*5-Phenyl-3-(m-tolyl)imidazo*[*1*,*5-c*]*quinazoline* (*3ac*). yellow solid, 75% yield, mp. 193 – 196 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.11 – 8.03 (m, 1H), 8.01 (s, 1H), 7.96 – 7.84 (m, 1H), 7.62 – 7.48 (m, 2H), 7.40 – 7.30 (m, 2H), 7.24 – 7.15 (m, 1H), 7.12 – 6.87 (m, 5H), 6.83 (s, 1H), 2.10 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  146.3, 142.8, 138.1, 136.9, 133.9, 131.2, 130.2, 129.8, 128.8, 128.40, 128.37, 128.1, 127.6, 127.5, 126.3, 121.7, 120.6, 119.3, 20.9; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>18</sub>N<sub>3</sub> [M+H]<sup>+</sup> 336.1495, found 336.1492.



5-*Phenyl-3-(p-tolyl)imidazo*[1,5-*c*]*quinazoline* (**3***a***d**). white solid, 71% yield, mp. 204 – 206 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.11 – 8.03 (m, 1H), 8.01 (s, 1H), 7.93 – 7.85 (m, 1H), 7.61 – 7.48 (m, 2H), 7.36 – 7.29 (m, 2H), 7.21 (t, *J* = 7.4 Hz, 1H), 7.07 (t, *J* = 7.6 Hz, 2H), 7.00 (d, *J* = 8.1 Hz, 2H), 6.82 (d, *J* = 8.0 Hz, 2H), 2.24 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 146.4, 142.9, 138.1, 138.0, 133.9, 130.1,

129.6, 129.0, 128.7, 128.6, 128.41, 128.36, 128.2, 128.1, 127.7, 121.7, 120.6, 119.4, 21.2; HRMS (ESI) m/z calcd for  $C_{23}H_{18}N_3$  [M+H]<sup>+</sup> 336.1495, found 336.1496.



3-(4-(Tert-butyl)phenyl)-5-phenylimidazo[1,5-c]quinazoline (**3ae**). yellow solid, 76% yield, mp. 188 – 189 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.12 – 8.04 (m, 1H), 8.02 (s, 1H), 7.97 – 7.87 (m, 1H), 7.61 – 7.50 (m, 2H), 7.32 – 7.26 (m, 2H), 7.19 – 7.10 (m, 1H), 7.07 – 6.98 (m, 6H), 1.24 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 151.1, 146.4, 142.9, 138.1, 133.8, 130.1, 129.6, 128.9, 128.7, 128.5, 128.44, 128.37, 128.2, 127.6, 124.4, 121.7, 120.6, 119.5, 34.5, 31.2; HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub> [M+H]<sup>+</sup> 378.1965, found 378.1968.



3-(4-Methoxyphenyl)-5-phenylimidazo[1,5-c]quinazoline (**3af**). yellow solid, 75% yield, mp. 189 – 190 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.12 – 8.02 (m, 1H), 8.00 (s, 1H), 7.94 – 7.85 (m, 1H), 7.61 – 7.49 (m, 2H), 7.33 (d, *J* = 7.2 Hz, 2H), 7.22 (d, *J* = 7.4 Hz, 1H), 7.10 (t, *J* = 7.6 Hz, 2H), 7.04 (d, *J* = 8.7 Hz, 2H), 6.55 (d, *J* = 8.7 Hz, 2H), 3.73 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.4, 146.3, 142.6, 138.0, 133.8, 130.5, 130.0, 129.8, 128.8, 128.4, 128.3, 128.2, 127.7, 124.0, 121.7, 120.5, 119.4, 113.0, 55.3; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>18</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 352.1444, found 352.1446.



3-(4-Fluorophenyl)-5-phenylimidazo[1,5-c]quinazoline (**3ag**). yellow solid, 85% yield, mp. 180 – 182 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.12 – 8.04 (m, 1H), 8.02 (s, 1H), 7.95 – 7.86 (m, 1H), 7.62 – 7.51 (m, 2H), 7.37 – 7.30 (m, 2H), 7.29 – 7.21 (m, 1H), 7.17 – 7.05 (m, 4H), 6.78 – 6.64 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.4 (d,  $J_{C-F}$  = 249.1 Hz), 146.0, 141.6, 138.1, 133.7, 131.0 (d,  $J_{C-F}$  = 8.5 Hz), 130.4, 130.1, 128.8, 128.6, 128.3, 127.9, 127.8 (d,  $J_{C-F}$  = 3.4 Hz), 121.8, 120.7, 119.3, 114.5 (d,  $J_{C-F}$  = 22.0 Hz); HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>15</sub>FN<sub>3</sub> [M+H]<sup>+</sup> 340.1245, found 340.1245.



3-(4-Chlorophenyl)-5-phenylimidazo[1,5-c]quinazoline (**3ah**). yellow solid, 76% yield, mp. 196 – 197 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 – 8.05 (m, 1H), 8.02 (s, 1H), 7.96 – 7.87 (m, 1H), 7.62 – 7.49 (m, 2H), 7.37 – 7.24 (m, 3H), 7.13 (t, *J* = 7.6 Hz, 2H), 7.09 – 6.96 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  145.9, 141.4, 138.1, 134.1, 133.6, 130.5, 130.3, 130.1, 130.0, 128.7, 128.62, 128.58, 128.2, 127.9, 127.6, 121.8, 120.8, 119.2; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>15</sub>ClN<sub>3</sub> [M+H]<sup>+</sup> 356.0949, found 356.0948.



3-(4-Bromophenyl)-5-phenylimidazo[1,5-c]quinazoline (3ai). yellow solid, 80% yield, mp. 185 – 188 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.11 – 8.04 (m, 1H), 8.02 (s, 1H), 7.96 – 7.88 (m, 1H), 7.62 – 7.51 (m, 2H), 7.36 – 7.27 (m, 3H), 7.21 – 7.06 (m, 4H), 7.04 – 6.91 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  145.9, 141.5, 138.1, 133.7, 130.58, 130.55, 130.47, 130.1, 128.8, 128.7, 128.6, 128.3, 128.0, 122.4, 121.8, 120.9, 119.2; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>15</sub>BrN<sub>3</sub> [M+H]<sup>+</sup> 400.0444, found 400.0441.



5-Phenyl-3-(4-(trifluoromethyl)phenyl)imidazo[1,5-c]quinazoline (**3a**j). yellow solid, 77% yield, mp. 170 – 173 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 – 8.07 (m, 1H), 8.06 (s, 1H), 7.96 – 7.89 (m, 1H), 7.63 – 7.54 (m, 2H), 7.35 – 7.27 (m, 4H), 7.25 – 7.19 (m, 3H), 7.13 – 7.05 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  145.7, 141.0, 138.2, 135.0, 133.6, 130.9, 130.2, 129.8(dd, *J*<sub>C-F</sub> = 65.2, 32.6 Hz), 129.4, 128.8, 128.71, 128.65, 128.3, 128.0, 124.2 (q, *J*<sub>C-F</sub> = 3.7 Hz), 123.8 (d, *J*<sub>C-F</sub> = 272.2 Hz), 121.9, 121.0, 119.1; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>15</sub>F<sub>3</sub>N<sub>3</sub> [M+H]<sup>+</sup> 390.1213, found 390.1215.



*3-(Naphthalen-1-yl)-5-phenylimidazo[1,5-c]quinazoline* (*3ak*). yellow solid, 90% yield, mp. 83 – 86 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.21 – 8.06 (m, 2H), 7.97 – 7.83 (m, 1H), 7.72 – 7.53 (m, 4H), 7.51 – 7.44 (m, 1H), 7.44 – 7.33 (m, 2H), 7.28 – 7.23 (m, 1H), 7.21 – 7.12 (m, 1H), 7.01 (brs, 2H), 6.90 – 6.82 (m, 1H), 6.65 (brs, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 146.5, 140.8, 138.2, 133.11, 133.06, 132.2, 130.0, 129.3, 129.23, 129.21, 128.61, 128.60, 128.4, 128.1, 127.7, 126.6, 125.9, 125.3, 124.5, 121.8, 120.7, 119.5; HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>18</sub>N<sub>3</sub> [M+H]<sup>+</sup> 372.1495, found 372.1493.



3-(*Furan-2-yl*)-5-phenylimidazo[1,5-c]quinazoline (**3al**). yellow oil, 62% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.09 – 8.02 (m, 1H), 8.01 (s, 1H), 7.95 – 7.87 (m, 1H), 7.61 – 7.52 (m, 2H), 7.52 – 7.44 (m, 2H), 7.39 – 7.31 (m, 1H), 7.30 – 7.20 (m, 2H), 6.86 (dd, *J* = 1.8, 0.8 Hz, 1H), 6.49 (dd, *J* = 3.4, 0.7 Hz, 1H), 6.19 (dd, *J* = 3.4, 1.8 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  146.1, 144.0, 143.4, 138.2, 134.1, 133.4, 130.4, 129.8, 128.8, 128.6, 128.3, 127.9, 127.7, 121.8, 121.0, 118.9, 112.0, 110.9; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>14</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 312.1131, found 312.1131.



5-Phenyl-3-(thiophen-2-yl)imidazo[1,5-c]quinazoline (**3am**). yellow solid, 76% yield, mp. 129 – 131 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 – 8.04 (m, 1H), 8.03 (s, 1H), 7.97 – 7.84 (m, 1H), 7.66 – 7.51 (m, 2H), 7.47 – 7.40 (m, 2H), 7.35 – 7.27 (m, 1H), 7.25 – 7.16 (m, 3H), 6.58 (dd, J = 5.1, 3.7 Hz, 1H), 6.33 (dd, J = 3.7, 1.1 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  146.0, 138.1, 136.2, 133.9, 132.2, 130.5, 130.1, 129.9, 128.64, 128.59, 128.3, 128.2, 127.9, 127.0, 126.8, 121.8, 121.1, 119.1; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>14</sub>N<sub>3</sub>S [M+H]<sup>+</sup> 328.0903, found 328.0906.



3an'

3-(*Pyridin-2-yl*)*imidazo*[1,2-*a*]*pyridine* (**3an**')<sup>12</sup>. yellow solid, 51% yield, mp. 68 – 70 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.96 (d, *J* = 7.3 Hz, 1H), 8.63 (d, *J* = 4.3 Hz, 1H), 8.35 (d, *J* = 8.1 Hz, 1H), 7.77 (td, *J* = 8.0, 1.7 Hz, 1H), 7.59 (s, 1H), 7.53 (d, *J* = 9.0 Hz, 1H), 7.19 (dd, *J* = 6.4, 5.0 Hz, 1H), 6.86 (dd, *J* = 8.5, 6.8 Hz, 1H), 6.73 (t, *J* = 6.4 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  151.2, 148.1, 136.5, 135.4, 132.9, 126.0, 121.7, 121.6, 121.0, 120.1, 118.0, 113.5; MS (ESI): 196.05 [M+H]<sup>+</sup>.



5-Phenylimidazo[1,5-c]quinazoline (**3ao**). yellow solid, 23% yield, mp. 140 – 142 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.27 (s, 1H), 8.04 – 7.96 (m, 1H), 7.95 – 7.87 (m, 3H), 7.86 (s, 1H), 7.66 – 7.58 (m, 3H), 7.57 – 7.47 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 145.4, 138.5, 133.0, 131.4, 130.1, 129.3,

128.7, 128.6, 128.5, 122.1, 121.1, 119.0; HRMS (ESI) m/z calcd for  $C_{16}H_{12}N_3$  [M+H]<sup>+</sup> 246.1026, found 246.1027.



*3-(Tert-butyl)-5-phenylimidazo*[*1*,*5-c*]*quinazoline* (*3ap*). yellow solid, 83% yield, mp. 109 – 112 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.97 – 7.88 (m, 1H), 7.83 – 7.73 (m, 2H), 7.67 – 7.59 (m, 2H), 7.56 – 7.39 (m, 5H), 1.14 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  152.1, 147.1, 138.5, 137.4, 131.2, 130.4, 128.8, 128.6, 128.2, 128.1, 127.6, 121.3, 119.8, 118.7, 35.9, 31.1; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub> [M+H]<sup>+</sup> 302.1652, found 302.1651.



5-(4-(*Tert-butyl*)*phenyl*)-3-*phenylimidazo*[1,5-*c*]*quinazoline* (**3ba**). white solid, 96% yield, mp. 176 – 179 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.10 – 8.04 (m, 1H), 8.02 (s, 1H), 7.96 – 7.86 (m, 1H), 7.61 – 7.50 (m, 2H), 7.24 – 7.18 (m, 2H), 7.13 – 7.04 (m, 5H), 7.03 – 6.93 (m, 2H), 1.22 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  153.2, 146.4, 142.7, 138.2, 131.7, 130.8, 130.3, 129.3, 128.4, 128.3, 128.2, 127.8, 127.3, 124.7, 121.7, 120.5, 119.3, 34.6, 31.1; HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub> [M+H]<sup>+</sup> 378.1965, found 378.1965.



5-(4-Methoxyphenyl)-3-phenylimidazo[1,5-c]quinazoline (**3**ca). yellow solid, 97% yield, mp. 146 – 148 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.12 – 8.03 (m, 1H), 8.01 (s, 1H), 7.94 – 7.82 (m, 1H), 7.60 – 7.48 (m, 2H), 7.30 – 7.23 (m, 2H), 7.19 – 7.10 (m, 3H), 7.10 – 7.02 (m, 2H), 6.68 – 6.43 (m, 2H), 3.72 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 160.9, 146.0, 142.7, 138.3, 131.7, 130.4, 130.3, 129.3, 128.4, 128.2, 128.0, 127.9, 127.4, 126.2, 121.7, 120.6, 119.2, 113.1, 55.4; HRMS (ESI) m/z calcd for  $C_{23}H_{18}N_3O$  [M+H]+ 352.1444, found 352.1443.



3-Phenyl-5-(4-(trifluoromethyl)phenyl)imidazo[1,5-c]quinazoline (3da). yellow solid, 79% yield,

mp. 219 – 222 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.15 – 8.06 (m, 1H), 8.05 (s, 1H), 7.94 – 7.87 (m, 1H), 7.65 – 7.52 (m, 2H), 7.43 (d, *J* = 8.1 Hz, 2H), 7.32 (d, *J* = 8.2 Hz, 2H), 7.19 – 7.11 (m, 1H), 7.11 – 6.97 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  144.7, 142.3, 137.9, 137.1, 131.7 (dd, *J*<sub>C-F</sub> = 66.4, 33.6 Hz), 131.2, 130.2, 129.3, 129.1, 129.0, 128.7, 128.5, 128.4, 127.7, 124.6 (q, *J*<sub>C-F</sub> = 3.7 Hz), 123.5 (d, *J*<sub>C</sub> = 272.4 Hz), 121.9, 120.9, 119.5; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>15</sub>F<sub>3</sub>N<sub>3</sub> [M+H]<sup>+</sup> 390.1213, found 390.1214.



5-(4-Nitrophenyl)-3-phenylimidazo[1,5-c]quinazoline (3ea). yellow solid, 80% yield, mp. 251 – 254 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.15 – 8.07 (m, 1H), 8.07 (s, 1H), 7.98 – 7.86 (m, 3H), 7.67 – 7.55 (m, 2H), 7.54 – 7.47 (m, 2H), 7.19 – 7.10 (m, 3H), 7.10 – 7.01 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 148.0, 143.8, 142.1, 139.7, 137.8, 131.0, 130.1, 129.7, 129.3, 129.2, 128.8, 128.7, 128.4, 127.8, 122.7, 121.9, 121.1, 119.4; HRMS (ESI) m/z calcd for  $C_{22}H_{15}N_4O_2$  [M+H]<sup>+</sup> 367.1190, found 367.1189.



5-(3-Chlorophenyl)-3-phenylimidazo[1,5-c]quinazoline (**3fa**). yellow solid, 90% yield, mp. 185 – 188 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.12 – 8.05 (m, 1H), 8.03 (s, 1H), 7.93 – 7.83 (m, 1H), 7.67 – 7.49 (m, 2H), 7.32 (t, J = 1.8 Hz, 1H), 7.26 – 7.06 (m, 7H), 7.01 (t, J = 7.9 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 144.7, 142.4, 137.9, 135.3, 133.9, 131.3, 130.2, 130.0, 129.1, 129.0, 128.8, 128.6, 128.5, 128.3, 127.7, 126.9, 121.8, 120.8, 119.4; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>15</sub>ClN<sub>3</sub> [M+H]<sup>+</sup> 356.0949, found 356.0949.





5-(2-Fluorophenyl)-3-phenylimidazo[1,5-c]quinazoline (**3ga**). yellow solid, 98% yield, mp. 185 – 187 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 – 8.05 (m, 1H), 8.01 (s, 1H), 7.95 – 7.86 (m, 1H), 7.65 – 7.48 (m, 3H), 7.23 – 6.98 (m, 7H), 6.58 – 6.46 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.1 (d,  $J_{C-F} = 250.1$  Hz), 142.8, 141.8, 137.8, 132.3 (d,  $J_{C-F} = 8.3$  Hz), 130.48 (d,  $J_{C-F} = 2.6$  Hz), 130.46, 129.7, 129.5, 128.9, 128.5, 128.3, 127.1, 124.3 (d,  $J_{C-F} = 3.3$  Hz), 123.1 (d,  $J_{C-F} = 14.5$  Hz), 121.9, 120.5, 119.7, 115.3 (d,  $J_{C-F} = 20.6$  Hz); HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>15</sub>FN<sub>3</sub> [M+H]<sup>+</sup> 340.1245, found 340.1242.



5-(*Furan-2-yl*)-3-phenylimidazo[1,5-c]quinazoline (**3ha**). yellow solid, 94% yield, mp. 220 – 222 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.09 – 8.01 (m, 1H), 8.00 (s, 1H), 7.93 – 7.83 (m, 1H), 7.61 – 7.48 (m, 2H), 7.44 – 7.32 (m, 2H), 7.30 – 7.17 (m, 3H), 6.93 – 6.86 (m, 1H), 6.86 – 6.78 (m, 1H), 6.26 (dd, *J* = 3.5, 1.8 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 145.7, 143.8, 143.0, 137.7, 137.0, 131.9, 130.3, 128.7, 128.5, 128.2, 128.1, 127.93, 127.85, 121.8, 120.8, 119.5, 114.6, 111.5; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>14</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 312.1131, found 312.1129.



*3-Phenyl-5-(thiophen-2-yl)imidazo*[*1*,*5-c*]*quinazoline* (*3ia*). yellow solid, 76% yield, mp. 213 – 216 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.12 – 7.99 (m, 2H), 7.94 – 7.83 (m, 1H), 7.65 – 7.47 (m, 2H), 7.34 – 7.25 (m, 3H), 7.24 – 7.10 (m, 3H), 6.68 (dd, *J* = 3.8, 1.1 Hz, 1H), 6.57 (dd, *J* = 5.0, 3.8 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  142.7, 140.5, 138.0, 134.7, 132.0, 131.1, 130.7, 128.6, 128.51, 128.50, 128.3, 128.1, 127.7, 126.6, 121.7, 120.9, 119.2; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>14</sub>N<sub>3</sub>S [M+H]<sup>+</sup> 328.0903, found 328.0897.



*3-Phenyl-5-(pyridin-3-yl)imidazo*[*1*,*5-c*]*quinazoline* (*3ja*). yellow solid, 98% yield, mp. 204 – 206 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.68 (d, *J* = 1.8 Hz, 1H), 8.42 (dd, *J* = 4.9, 1.5 Hz, 1H), 8.12 – 8.05 (m, 1H), 8.04 (s, 1H), 7.97 – 7.85 (m, 1H), 7.66 – 7.54 (m, 2H), 7.54 – 7.46 (m, 1H), 7.21 – 7.04 (m, 5H), 6.94 (dd, *J* = 7.9, 4.9 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  150.4, 149.3, 143.4, 142.2, 137.9, 135.5, 130.9, 130.13, 130.10, 129.6, 129.0, 128.7, 128.6, 128.3, 127.9, 122.1, 121.8, 120.9, 119.4; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>15</sub>N<sub>4</sub> [M+H]<sup>+</sup> 323.1291, found 323.1287.



3ka

5-*Methyl-3-phenylimidazo[1,5-c]quinazoline (3ka)*. white solid, 76% yield, mp. 154 – 155 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.01 – 7.90 (m, 1H), 7.85 (s, 1H), 7.78 – 7.68 (m, 1H), 7.60 – 7.53 (m, 2H), 7.53 – 7.41 (m, 5H), 2.34 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 145.0, 141.9, 137.7, 132.8, 130.7,

129.7, 129.3, 128.4, 128.1, 127.9, 127.3, 121.7, 119.9, 119.5, 24.7; HRMS (ESI) m/z calcd for  $C_{17}H_{14}N_3$  [M+H]<sup>+</sup> 260.1182, found 260.1179.





*3-Phenyl-5-propylimidazo*[*1*,5-*c*]*quinazoline* (*3la*). yellow solid, 55% yield, mp. 78 – 81 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.00 – 7.94 (m, 1H), 7.87 (s, 1H), 7.78 – 7.71 (m, 1H), 7.60 – 7.42 (m, 7H), 2.74 – 2.47 (m, 2H), 1.65 – 1.52 (m, 2H), 0.63 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  148.2, 141.6, 137.7, 133.0, 130.4, 129.6, 129.5, 128.3, 128.1, 127.8, 127.5, 121.6, 120.0, 119.3, 37.3, 20.4, 13.4; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>18</sub>N<sub>3</sub> [M+H]<sup>+</sup> 288.1495, found 288.1495.



5-(*Tert-butyl*)-3-phenylimidazo[1,5-c]quinazoline (**3ma**). yellow oil, 91% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.99 – 7.85 (m, 2H), 7.80 – 7.70 (m, 1H), 7.60 – 7.51 (m, 2H), 7.51 – 7.35 (m, 5H), 1.25 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 154.3, 143.1, 137.0, 135.3, 131.8, 131.0, 129.4, 128.2, 128.1, 127.9, 127.5, 121.1, 120.7, 119.2, 40.2, 30.0; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub> [M+H]<sup>+</sup> 302.1652, found 302.1651.



5-*Cyclopropyl-3-phenylimidazo*[*1*,5-*c*]*quinazoline* (*3na*). yellow solid, 91% yield, mp. 112 – 114 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.09 – 7.91 (m, 1H), 7.88 (s, 1H), 7.70 – 7.62 (m, 3H), 7.51 – 7.41 (m, 5H), 1.74 (tt, *J* = 8.1, 4.9 Hz, 1H), 1.42 – 1.31 (m, 2H), 0.83 – 0.70 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  149.2, 141.8, 137.8, 133.1, 130.3, 129.7, 129.3, 128.2, 128.0, 127.3, 127.2, 121.6, 120.1, 119.1, 15.6, 10.8; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>16</sub>N<sub>3</sub> [M+H]<sup>+</sup> 286.1339, found 286.1339.



5-Cyclohexyl-3-phenylimidazo[1,5-c]quinazoline (**3**0*a*). white solid, 87% yield, mp. 153 – 156 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.00 – 7.94 (m, 1H), 7.89 (s, 1H), 7.81 – 7.73 (m, 1H), 7.60 – 7.43 (m, 7H), 2.88 – 2.72 (m, 1H), 1.82 – 1.71 (m, 2H), 1.67 – 1.42 (m, 5H), 1.22 – 1.03 (m, 1H), 0.75 – 0.51

(m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  152.1, 141.3, 137.8, 133.6, 130.2, 129.7, 129.5, 128.21, 128.19, 127.7, 127.6, 121.6, 119.9, 119.3, 40.7, 30.9, 25.7, 25.6; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub> [M+H]<sup>+</sup> 328.1808, found 328.1809.



*N-Benzyl-3-phenylimidazo*[*1*,5-*c*]*quinazolin-5-amine* (*3pa*'). yellow solid, 8% yield, mp. 33 – 35 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.90 (d, *J* = 7.7 Hz, 1H), 7.82 (s, 1H), 7.63 – 7.54 (m, 3H), 7.49 – 7.34 (m, 5H), 7.32 – 7.21 (m, 3H), 7.13 – 7.05 (m, 2H), 5.12 (brs, 1H), 4.64 (d, *J* = 5.0 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  141.3, 139.9, 139.5, 137.4, 131.2, 131.1, 130.5, 130.1, 128.57, 128.56, 127.7, 127.5, 125.1, 123.9, 121.8, 120.1, 116.6, 45.8; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 351.1604, found 351.1603.



*3-Phenyl-5-(piperidin-1-yl)imidazo*[*1*,*5-c*]*quinazoline* (*3qa*). yellow solid, 37% yield, mp. 163 – 165 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.93 (dd, *J* = 7.8, 1.1 Hz, 1H), 7.88 (s, 1H), 7.73 – 7.63 (m, 3H), 7.49 – 7.40 (m, 4H), 7.37 (td, *J* = 7.7, 1.1 Hz, 1H), 3.33 (brs, 2H), 2.72 (brs, 2H), 1.36 (brs, 4H), 0.71 (brs, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  146.8, 142.3, 139.2, 131.8, 131.6, 130.5, 128.7, 128.3, 127.3, 126.4, 125.7, 121.6, 120.9, 118.3, 50.5, 24.0, 23.7; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>21</sub>N<sub>4</sub> [M+H]<sup>+</sup> 329.1761, found 329.1763.



*4-(3-Phenylimidazo*[*1*,*5-c*]*quinazo*l*in-5-yl*)*morpholine* (*3ra*). yellow solid, 48% yield, mp. 173 – 175 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.94 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.90 (s, 1H), 7.75 – 7.64 (m, 3H), 7.52 – 7.43 (m, 4H), 7.40 (td, *J* = 7.6, 1.3 Hz, 1H), 3.80 – 2.50 (m, 8H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  145.7, 141.9, 138.8, 131.8, 131.6, 130.5, 129.1, 128.5, 127.5, 126.6, 126.2, 121.7, 121.1, 118.4, 64.9, 49.7; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 331.1553, found 331.1552.



3,5-Diphenyl-[1,3]dioxolo[4,5-g]imidazo[1,5-c]quinazoline (**3sa**). yellow solid, 35% yield, mp. 201 – 203 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.87 (s, 1H), 7.39 (s, 1H), 7.32 – 7.28 (m, 3H), 7.18 (t, *J* = 7.5 Hz, 1H), 7.13 – 6.97 (m, 7H), 6.10 (s, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  148.6, 148.4, 144.5, 141.6, 134.2, 133.8, 131.5, 130.8, 129.7, 129.1, 128.6, 127.9, 127.7, 127.4, 119.2, 114.4, 107.2, 101.9, 99.9; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 366.1237, found 366.1234.



3,5-Diphenylimidazo[1,5-c]pyrido[3,2-e]pyrimidine (**3ta**). yellow solid, 69% yield, mp. 220 – 223 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.81 (d, *J* = 3.2 Hz, 1H), 8.40 (d, *J* = 6.6 Hz, 1H), 8.09 (s, 1H), 7.50 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.42 (d, *J* = 7.4 Hz, 2H), 7.22 – 7.11 (m, 4H), 7.10 – 6.98 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  150.1, 149.6, 149.3, 143.4, 133.0, 131.0, 130.49, 130.48, 129.8, 129.1, 129.0, 128.4, 127.55, 127.52, 123.3, 122.2, 114.7; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>15</sub>N<sub>4</sub> [M+H]<sup>+</sup> 323.1291, found 323.1290.



(2-Phenylquinazolin-4-yl)methyl acetate (**6**). yellow solid, 52% yield, mp. 87 – 90 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.68 – 8.56 (m, 2H), 8.12 (d, J = 8.4 Hz, 1H), 8.08 – 7.99 (m, 1H), 7.89 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.60 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.57 – 7.48 (m, 3H), 5.77 (s, 2H), 2.27 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 170.6, 163.6, 160.1, 151.1, 137.8, 133.9, 130.7, 129.5, 128.6, 127.4, 123.8, 121.3, 64.2, 20.9; MS (ESI): 279.05 [M+H]<sup>+</sup>; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup> 279.1128, found 279.1127.

#### References

- 1. K. Karnakar, J. Shankar, S. N. Murthy, K. Ramesh and Y. V. D. Nageswar, Synlett, 2011, 1089.
- 2. Y.-C. Chen and D.-Y. Yang, Tetrahedron, 2013, 69, 10438.
- 3. F. Portela-Cubillo, J. S. Scott and J. C. Walton, Chem. Commun., 2008, 2935.
- 4. Z.-H. Zhang, X.-N. Zhang, L.-P. Mo, Y.-X. Li and F.-P. Ma, Green Chem., 2012, 14, 1502.
- 5. F. Portela-Cubillo, J. S. Scott and J. C. Walton, J. Org. Chem., 2009, 74, 4934.
- R. Alonso, A. Caballero, P. J. Campos, D. Sampedro and M. A. Rodríguez, *Tetrahedron*, 2010, 66, 4469.
- 7. C. Huang, Y. Fu, H. Fu, Y. Jiang and Y. Zhao, Chem. Commun., 2008, 6333.
- 8. W. L. F. Armarego and J. I. C. Smith, J. Chem. Soc. C, 1966, 234.
- 9. I. Mangalagiu, T. Benneche and K. Undheim, Tetrahedron Lett., 1996, 37, 1309.
- 10. X. Huang, H. Yang, H. Fu, R. Qiao and Y. Zhao, Synthesis, 2009, 2679.
- 11. X. Zheng, B. Song and B. Xu, Eur. J. Org. Chem., 2010, 4376.
- 12. B. Liu, Y. Huang, J. Lan, F. Song and J. You, Chem. Sci., 2013, 4, 2163.



#### Spectral copies of <sup>1</sup>H- and <sup>13</sup>C-NMR of products and intermediate 6















































![](_page_45_Figure_1.jpeg)

![](_page_46_Figure_1.jpeg)

![](_page_47_Figure_1.jpeg)

![](_page_48_Figure_1.jpeg)

--2.34

![](_page_49_Figure_0.jpeg)

![](_page_50_Figure_1.jpeg)

# 0

![](_page_51_Figure_1.jpeg)

![](_page_52_Figure_1.jpeg)

![](_page_53_Figure_1.jpeg)

![](_page_54_Figure_0.jpeg)

![](_page_54_Figure_1.jpeg)

![](_page_55_Figure_1.jpeg)

![](_page_56_Figure_0.jpeg)

![](_page_57_Figure_1.jpeg)

![](_page_58_Figure_0.jpeg)